InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
0
T+90 hit rate
14%
T+90 mean return
-6.5%
Across 14 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Suria Hamza, Chairman & CEO. Insider active across 1 company, notably Anaptysbio, INC. Cumulatively, 14 reports have been recorded. History available since 12 May 2021. The latest transaction was filed on 20 December 2021 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations14 total
36,645 shares@ US$1.120.0020% mcap27.9% of flowCommon StockSEC:0001209191-21-070986
36,645 shares@ US$1.120.0020% mcap14.0% of flowCommon StockSEC:0001209191-21-070986:0
964 shares@ US$22.030.0010% mcap7.1% of flowCommon StockSEC:0001209191-21-065173:0
964 shares@ US$22.030.0010% mcap14.2% of flowCommon StockSEC:0001209191-21-065173
6,059 shares@ US$1.120.0003% mcap4.5% of flowCommon StockSEC:0001209191-21-063263
6,059 shares@ US$1.120.0003% mcap2.2% of flowCommon StockSEC:0001209191-21-063263:0
36,646 shares@ US$1.120.0019% mcap13.6% of flowCommon StockSEC:0001209191-21-062481:0
36,646 shares@ US$1.1213.6% of flowCommon StockSEC:0001209191-21-062481
15,993 shares@ US$1.120.0008% mcap5.9% of flowCommon StockSEC:0001209191-21-061975:0
15,993 shares@ US$1.125.9% of flowCommon StockSEC:0001209191-21-061975
10,000 shares@ US$1.120.0005% mcap3.6% of flowCommon StockSEC:0001209191-21-057077:0
10,000 shares@ US$1.123.6% of flowCommon StockSEC:0001209191-21-057077
10,000 shares@ US$1.120.0005% mcap3.5% of flowCommon StockSEC:0001209191-21-032377:0
10,000 shares@ US$1.123.5% of flowCommon StockSEC:0001209191-21-032377
14 of 14 declarations
About Suria Hamza
Hamza Suria is the President & CEO at ANAPTYSBIO, INC. He is responsible for the strategic and operational direction of the company, overseeing growth and innovation initiatives. His leadership is essential in ensuring success and competitiveness for Anaptysbio in the market.
